Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA

DW Hiller, HM Earl, JA Dunn, Sarah Bathers, David Spooner, R Grieve, RK Agrawal, CJ Poole

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)p25
JournalMeetings Proceedings book Abstract no 595
Publication statusPublished - 1 Jan 2004

Cite this